Revexa Pharma Retatrutide 40mg Pen

Revexa Pharma Retatrutide is a triple-receptor agonist peptide that targets GLP-1, GIP, and glucagon receptors simultaneously, delivering the most aggressive non-surgical fat loss currently available. In the phase 2 NEJM trial (2023), the highest-dose group lost an average of 24.2% of body weight over 48 weeks, surpassing both Semaglutide (14.9%) and Tirzepatide (22.5%) in their respective landmark studies. Revexa Pharma’s formulation provides pharmaceutical-grade Retatrutide tested for purity and accurate peptide content.

How Retatrutide Differs from Semaglutide

While Semaglutide acts on GLP-1 receptors only, Retatrutide adds two additional mechanisms. The GIP receptor activation amplifies appetite suppression beyond what GLP-1 alone achieves. The glucagon receptor activation is unique to Retatrutide: it stimulates the liver to burn stored fat directly and raises resting metabolic rate, meaning you burn more calories even at rest. This three-pronged approach targets fat through appetite reduction, improved metabolic signalling, and direct hepatic fat oxidation simultaneously.

For bodybuilders and athletes, the glucagon component is particularly valuable because it preferentially targets visceral fat, the metabolically active abdominal fat that is the most stubborn to lose through diet and cardio alone. Users consistently report that the midsection responds earliest and most dramatically during Retatrutide use.

Dosage Protocol

Retatrutide requires gradual escalation over 12 weeks to minimise GI side effects:

• Week 1-4: 1mg subcutaneous injection once weekly
• Week 5-8: 2-4mg once weekly
• Week 9-12: 4-8mg once weekly
• Week 13+: 8-12mg once weekly (target maintenance dose)
• Injection site: abdomen or thigh, rotating sides weekly
• Timing: same day each week, morning or evening

Combining Retatrutide with Steroid Cycles

Retatrutide stacks well with cutting compounds because it addresses the appetite and metabolic side of fat loss while steroids handle the muscle-preservation side:

• With Anavar: Retatrutide suppresses appetite and boosts metabolism while Anavar preserves lean tissue and adds hardness. An excellent non-stimulant cutting stack
• Post-bulk appetite control: after a Dianabol or Deca bulk, appetite can remain elevated for weeks. Retatrutide resets satiety signals and prevents excessive fat regain during the transition to maintenance
• Contest prep: Retatrutide’s steady, predictable fat loss is easier to plan around than stimulant-based approaches with variable daily effects

Side Effects

• Nausea: most common during dose escalation. Taking the injection at bedtime and staying hydrated reduces severity. Resolves for most users within 2-4 weeks at each dose level
• Diarrhoea or constipation: GI adjustment. Usually temporary
• Pronounced appetite suppression: ensure minimum protein intake of 2g per kg bodyweight to prevent muscle loss. Force-feed protein if necessary
• Mild heart rate increase: 2-4 bpm on average. Monitor if stacking with stimulants
• No testosterone suppression, no liver toxicity, no PCT required

Key Facts

• Active ingredient: Retatrutide
• Manufacturer: Revexa Pharma
• Class: GLP-1/GIP/Glucagon triple receptor agonist
• Half-life: approximately 6 days (once-weekly dosing)
• Storage: refrigerate. Protect from light

Also available: Vitalyn Biotech Retatrutide. Browse our full weight loss range including Semaglutide, Tirzepatide, and Clenbuterol.